Long noncoding RNA ENST00000434223 suppressed tumor progression in non-small cell lung cancer
In spite of the fact that the great progress has been made in the treatment of non-small cell lung cancer (NSCLC), the prognosis of NSCLC remains comparatively dismal. Therefore, it is of great value to identify novel effective diagnostic biomarkers and therapeutic targets of NSCLC. Emerging evidence has demonstrated the vital roles of long noncoding RNAs (lncRNAs) in cancer development. ENST00000434223 was recently identified as a lncRNA that is downregulated in early stage lung adenocarcinoma in a profiling study. However, little is known about its role in the development of NSCLC. In the present study, we found that ENST00000434223 was greatly downregulated in cancer tissues compared to adjacent normal tissues. ENST00000434223 overexpression suppressed the proliferation and migration in NSCLC cell lines in vitro. Moreover, ENST00000434223 overexpression reversed the epithelial-mesenchymal transition in NSCLC cell line. Our study suggests that ENST00000434223 may be a potential biomarker and a therapeutic target of NSCLC.
KeywordsNon-small cell lung cancer Long noncoding RNA ENST00000434223 Epithelial-mesenchymal-transition
Compliance with ethical standards
Understanding and written consent of each subject were obtained. This study was approved by the Human Ethics Committee of Chest Hospital at JIAOTONG University (Shanghai, China).
The animal care and experimental protocols were approved by the institutional guidelines of Zhengzhou University.
Conflicts of interest